

AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. to 3. (**canceled**)

4. (**withdrawn**) An axon growth stimulation kit as defined in claim 1 wherein said therapeutically acceptable matrix is a fibrin matrix.

5. to 6. (**canceled**)

7. (**withdrawn**) A biocompatible composition as defined in claim 5 wherein said therapeutically acceptable matrix is a fibrin matrix.

8. (**withdrawn**) A method for the preparation of a flowable biocompatible composition comprising admixing (i) at least one supplement selected from the group consisting of therapeutically active agents for facilitating axon growth and (ii) a flowable carrier component capable of forming a therapeutically acceptable matrix in vivo at a nerve lesion site; wherein said supplement is releasable from said matrix into the adjacent external environment.

9. (**withdrawn**) A method as defined in claim 8 wherein said therapeutically acceptable matrix is a collagen matrix.

10. (**withdrawn**) A method as defined in claim 8 wherein said therapeutically acceptable matrix is a fibrin matrix.

11. (**new**) An axon sprouting stimulation kit comprising

- a first container comprising a flowable collagen matrix,
- a second container comprising a matrix-releasable therapeutically active agent,
- a mixing means for intermingling the flowable collagen matrix and the matrix-releasable therapeutically active agent into a therapeutically acceptable matrix, and;
- a delivery means,

wherein the matrix-releasable therapeutically active agent is selected from the group consisting of C3 and Y-27632 for facilitating axon sprouting at a nerve lesion

site.

12. (new) The axon sprouting stimulation kit of claim 11, wherein C3 is selected from the group consisting of ADP-ribosyl transferase C3 derived from Clostridium botulinum and a recombinant C3 retaining ADP-ribosylation activity.

13. (new) The axon sprouting stimulation kit of claim 11, further comprising a protease inhibitor.

14. (new) The axon sprouting stimulation kit of claim 13, wherein said protease inhibitor is aprotinin.

15. (new) The axon sprouting stimulation kit of claim 13, wherein C3 is selected from the group consisting of ADP-ribosyl transferase C3 derived from Clostridium botulinum and a recombinant C3 retaining ADP-ribosylation activity.

16. (new) An axon sprouting stimulation kit comprising

- a container comprising a flowable collagen matrix and a matrix-releasable therapeutically active agent, and;
- a delivery means,

wherein the matrix-releasable therapeutically active agent is selected from the group consisting of C3 and Y-27632 for facilitating axon sprouting at a nerve lesion site.

17. (new) The axon sprouting stimulation kit of claim 16, wherein C3 is selected from the group consisting of ADP-ribosyl transferase C3 derived from Clostridium botulinum and a recombinant C3 retaining ADP-ribosylation activity.

18. (new) The axon sprouting stimulation kit of claim 16, further comprising a protease inhibitor.

19. (new) The axon sprouting stimulation kit of claim 18, wherein said protease inhibitor is aprotinin.

20. (new) The axon sprouting stimulation kit of claim 18, wherein C3 is selected from the group consisting of ADP-ribosyl transferase C3 derived from Clostridium

botulinum and a recombinant C3 retaining ADP-ribosylation activity.

21. (new) A biocompatible composition for facilitating axon sprouting, said composition comprising: (i) a therapeutically active agent selected from the group consisting of C3 and Y-27632 for facilitating axon sprouting, and (ii) a flowable collagen matrix.

22. (new) The biocompatible composition of claim 21, wherein C3 is selected from the group consisting of ADP-ribosyl transferase C3 derived from Clostridium botulinum, and a recombinant C3 retaining ADP-ribosylation activity.